Nonalcoholic fatty liver disease (NAFLD) has been associated with relative skeletal muscle mass in several cross-sectional studies. We explored the effects of relative skeletal muscle mass and changes in relative muscle mass over time on the development of incident NAFLD or the resolution of baseline NAFLD in a large, longitudinal, population-based 7-year cohort study. We included 12,624 subjects without baseline NAFLD and 2943 subjects with baseline NAFLD who underwent health check-up examinations. A total of 10,534 subjects without baseline NAFLD and 2631 subjects with baseline NAFLD were included in analysis of changes in relative skeletal muscle mass over a year. Subjects were defined as having NAFLD by the hepatic steatosis index, a previously validated NAFLD prediction model. Relative skeletal muscle mass was presented using the skeletal muscle mass index (SMI), a measure of body weight-adjusted appendicular skeletal muscle mass, which was estimated by bioelectrical impedance analysis. Of the 12,624 subjects without baseline NAFLD, 1864 (14.8%) developed NAFLD during the 7-year follow-up period. Using Cox proportional hazard analysis, compared with the lowest sex-specific SMI tertile at baseline, the highest tertile was inversely associated with incident NAFLD (adjusted hazard ratio N onalcoholic fatty liver disease (NAFLD), one of the most common metabolic liver diseases, is associated with increasing health and socioeconomic burdens worldwide.
N onalcoholic fatty liver disease (NAFLD), one of the most common metabolic liver diseases, is associated with increasing health and socioeconomic burdens worldwide.
(1) More than one-third of American adults are estimated to have NAFLD, (2) and the prevalence of NAFLD in Asian populations is similar to that of European populations, ranging from 15% to 45%. Increases in NAFLD prevalence are associated with sedentary lifestyles and increasing rates of metabolic diseases such as obesity, metabolic syndrome, and diabetes. (3) NAFLD ranges from simple steatosis to progressive nonalcoholic steatohepatitis (NASH), which is associated with high mortality from complications of liver disorders and cardiovascular disease. (4) However, no drugs are yet approved by the Food and Drug Administration for treating NAFLD, and therefore research has focused on a variety of interventions and medications for preventing or improving NAFLD. (5) Skeletal muscle has been regarded as an important endocrine organ for postprandial glucose utilization and secretion of myokines that mediate crosstalk among muscle, liver, adipose tissue, and other organs. (6, 7) Several studies have reported that low muscle mass is associated with the prevalence of NAFLD in cross-sectional settings, (8) (9) (10) (11) but longitudinal data exploring the causal relationship between low muscle mass and NAFLD are limited. In addition, the effect of skeletal muscle mass on the resolution of existing NAFLD is poorly understood. Losses of skeletal muscle mass may lead to metabolic impairments and aggravate NAFLD across the entire age range of the population beyond sarcopenia, age-related muscle mass loss, (12, 13) but evidence regarding the relationship between changes in skeletal muscle mass over time and the development or resolution of NAFLD is scarce. Therefore, in this study, we explore whether relative skeletal muscle mass and changes in relative muscle mass over time are associated with either the development of NAFLD or the resolution of existing baseline NAFLD in a large population-based 7-year longitudinal study.
Patients and Methods

StUDy SUBJeCtS
In this longitudinal cohort study, we enrolled 20,069 subjects age 20 years or older who underwent four or more follow-up comprehensive health examinations either annually or biennially from August 2006 through August 2013 at the Health Promotion Center at Samsung Medical Center, Seoul, Republic of Korea. Industrial Safety and Health Law requires health screening examinations of all employees annually or biennially without any charge in the Republic of Korea. The study population consisted of employees of various organizations and companies, and subjects who voluntarily took part in the annual or biennial comprehensive health screening examinations at the center. Subjects with missing data for baseline skeletal muscle mass (n = 355), waist circumference, body weight, or laboratory results (n = 1294), and subjects with positive serologic markers of hepatitis B virus (n = 822) or hepatitis C (n = 161) or daily alcohol consumption greater than 30 g for men and greater than 20 g for women (n = 1039) or missing data for alcohol consumption (n = 851) were excluded ( Fig. 1) . Finally, 15,567 individuals were included in analyses and categorized according to the presence of NAFLD based on the hepatic steatosis index (HSI). To investigate the relationship between skeletal muscle mass and incident NAFLD, we analyzed subjects without baseline NAFLD (n = 12,624). The relationship between changes in skeletal muscle mass and incident NAFLD was examined in 10,534 subjects after excluding subjects with missing data for 1-year follow-up skeletal muscle mass (n = 947) and laboratory results (n = 322) or with NAFLD at year 1 (n = 821). The relationship between baseline skeletal muscle mass and resolution of existing NAFLD was evaluated in 2943 subjects with NAFLD at baseline. To examine the relationship between change in skeletal muscle mass and the resolution of existing NAFLD, we further excluded subjects with missing data for 1-year follow-up skeletal muscle mass (n = 227) and laboratory results (n = 67) or with resolution of NAFLD at year 1 (n = 18). A total of 2631 subjects were analyzed. The Institutional Review Board (IRB) of Samsung Medical Center aRtiCle iNFoRmatioN: approved this study protocol (No. 2017-10-072) and the informed consent requirement was waived by the IRB, because the study information was de-identified.
meaSURemeNtS oF CliNiCal VaRiaBleS aND BioCHemiCal Data
Personal and family medical history, smoking history, exercise, alcohol consumption, medication, anthropometric measurements, and laboratory data were collected. Smoking status was categorized as never, past smoker, or current smoker. Exercise status was assessed as none or regular exercise. Body weight and height were measured and body mass index (BMI) was calculated as body weight (kg) divided by height squared (m 2 ). Obesity was defined according to the criteria for the Asian and Pacific regions (BMI ≥ 25 kg/m 2 ). (13) Waist circumference was measured at the narrowest level between the upper iliac crest and lowest rib after normal expiration. Blood pressure was measured using a mercury sphygmomanometer after at least 5 minutes of rest in a sitting position.
Venous blood samples were collected after an overnight fast. Plasma total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine were measured using a Modular D2400 (Roche Diagnostics, Basel, Switzerland). The presence of hepatitis B surface antigen and anti-hepatitis C virus antibody was also measured. High-sensitivity C-reactive protein (CRP) was determined using the CRP (II) Latax X2 turbidimetric method (Hitachi Corporation, Tokyo, Japan). Plasma glucose and insulin levels were measured using the hexokinase method with Bayer Reagent Packs on an automated chemistry analyzer (Advia 1650 Autoanalyzer; Bayer Diagnostics, Leverkusen, Germany) and an immunoradiometric assay (DIAsource Co., Louvain-la-Neuve, Belgium), respectively. Hemoglobin A1c (HbA1C) level was determined by high-performance liquid chromatography on an HLC-723G8 automated glycohemoglobin analyzer (TOSOH, Yokkaichi, Japan). Homeostasis model assessment of insulin resistance (HOMA-IR) was determined by the following formula: fasting plasma insulin (μIU/mL) × fasting plasma glucose (mg/dL)/405. (15) Estimated glomerular filtration rate was calculated using the modification of diet in renal disease equation. (16) In this study, we defined impaired fasting glucose (IFG) as a fasting glucose level of 100 to 125 mg/dL or an HbA1C level of 5.7% to 6.4% without taking antidiabetic medication, and we defined diabetes as fasting glucose level greater than or equal to 126 mg/dL, HbA1C level greater than or equal to 6.5%, or use of antidiabetic medication. (17) Hypertension was defined as blood pressure greater than or equal to 140/90 mmHg or use of antihypertensive medication. Metabolic syndrome was defined according to the revised National Cholesterol Education Program definition as having three or more of the following components: waist circumference greater than or equal to 90 cm in men or greater than or equal to 80 cm in women using the Asia-Pacific abdominal obesity criteria; serum triglycerides greater than or equal to 150 mg/dL or medication use; HDL cholesterol level less than 40 mg/dL in men or less than 50 mg/dL in women; blood pressure greater than or equal to 130/85 mmHg or the use of antihypertensive drugs; and serum glucose greater than or equal to 100 mg/dL or taking antidiabetic medication. (18) 
meaSURemeNt oF appeNDiCUlaR SKeletal mUSCle maSS aND DeFiNitioN oF SKeletal mUSCle maSS iNDeX
We conducted bioelectrical impedance analysis (BIA) to estimate appendicular skeletal muscle mass (ASM) for each limb (kg) using a multifrequency BIA device according to the manufacturer's instructions (InBody 720; Biospace Inc., Seoul, Korea) after an overnight fast.
The BIA technique was validated for the assessment of body composition, showing good correlation with dual-energy x-ray absorptiometry, and applied to estimate ASM in several recent studies. (19) (20) (21) (22) (23) The skeletal muscle mass index (SMI) was calculated by dividing the sum of the ASM in the bilateral upper and lower four limbs (kg) by body weight (kg) and expressed as a percentage (= total ASM/body weight × 100%) as a modified formula from the study of Janssen et al. (11, (23) (24) (25) (26) Change in SMI over the course of 1 year from baseline was calculated by subtracting baseline SMI from SMI at the 1-year follow-up visit. Also, change in SMI over a longer time was defined by subtracting baseline SMI from SMI at the follow-up visit. In addition, ASM/BMI, another SMI, developed by the National Institutes of Health Sarcopenia Project, was also adopted for sensitivity analysis. (27) 
DeFiNitioN oF NaFlD
NAFLD was defined using a previously validated fatty liver prediction model of HSI (>36.0) with the following formula: 8 × ALT/AST ratio + BMI (+2, if diabetes; +2, if female). (28, 29) Resolution of NAFLD was defined as less than 30.0 of HSI from existing baseline NAFLD. HSI was previously well-validated by liver biopsy and measurement tools including abdominal ultrasonography, controlled attenuation parameter (CAP), or proton magnetic resonance spectroscopy (MRS) in large multiethnic samples and reflected the degree of NAFLD as well as changes in NAFLD. (30) (31) (32) (33) 
StatiStiCal aNalySiS
All continuous variables are presented as mean ± SD, and categorical variables are expressed as frequencies with percentages. Data were partly extracted from the Clinical Data Warehouse Darwin-C of Samsung Medical Center. Analysis of variance tests were conducted for continuous variables and chi-square tests for categorical variables. Paired t-tests were used to compare variables at baseline and those at follow-up year 1. Correlations between changes in SMI and changes in HSI and glycometabolic parameters were analyzed using Pearson's correlation. An analysis of covariance (ANCOVA) model was used to compare SMI at the last follow-up visit after adjusting for the corresponding baseline SMI. Cumulative event rates for incident NAFLD were estimated by KaplanMeier survival curves, and equalities were compared with the log-rank test. Cox proportional hazard analysis was performed to determine independent associations between either baseline SMI or changes in SMI over 1 year and the development or resolution of NAFLD. For multivariable-adjusted analyses, model 1 was adjusted for age, sex, and waist circumference; model 2 was further adjusted for diabetes, hypertension, smoking status, and regular exercise; model 3 was further adjusted for SMI at baseline. All covariates in the multivariate models had a variance inflation factor less than 5.0, which was considered adequate to avoid multicollinearity. In addition, we performed subgroup analyses defined by sex, age (≤ 50 years, > 50 years), obesity, hypertension, or insulin resistance (HOMA-IR ≤ 2.5, > 2.5). P values less than 0.05 were considered statistically significant. Statistical analyses were performed using SPSS version 23.0 for Windows (SPSS Inc., Chicago, IL).
Results
BaSeliNe CHaRateRiStiCS oF StUDy SUBJeCtS aCCoRDiNg to SeX-SpeCiFiC Smi teRtile aND pReSeNCe oF NaFlD
Among a total of 15,567 subjects, women comprised 41.6%, mean age was 51.4 ± 8.3 years, and mean BMI was 23.8 ± 2.8 kg/m 2 . The prevalence of NAFLD at baseline was 18.9% (n = 2943; Table 1 ). Compared with subjects with the lowest baseline SMI tertile, those with middle or highest baseline SMI tertile were more likely to be younger, less obese, and have greater ASM, lower blood pressure, lower prevalence of IFG or metabolic syndrome, and metabolically healthier glycometabolic laboratory parameters both with and without baseline NAFLD status.
RelatioNSHip BetWeeN BaSeliNe Smi aND iNCiDeNt NaFlD
Mean follow-up time was 56.1 ± 12.4 months for a total of 15,567 participants (Supporting Table S1 ). Of the 12,624 subjects without baseline NAFLD, 1864 (14.8%) developed NAFLD during the 7-year follow-up period. The cumulative incidence of NAFLD was significantly lower in subjects in higher tertiles of baseline SMI compared with those with the lowest tertile ( Fig. 2 , P < 0.001 by log-rank test). Cox proportional hazard regression analyses were conducted to examine the independent association of baseline SMI with the development of NAFLD (Table 2) . Compared with subjects in the lowest baseline SMI tertile, those in the highest baseline SMI tertile were significantly associated with a decreased adjusted hazard ratio (AHR = 0.44, 95% confidence interval [CI] = 0.38-0.51, P < 0.001) for incident NAFLD after adjusting for age, sex, waist circumference, diabetes, hypertension, smoking status, and regular exercise (model 2; Table 2 ). Consistent with these results, subjects in higher sex-specific ASM/BMI tertiles at baseline showed a significant inverse association with NAFLD compared with those in the lowest sexspecific ASM/BMI tertile (Supporting Table S2 ). In subgroup analyses, this inverse association between baseline SMI and incident NAFLD was consistent across indicated subgroups (P for interaction > 0.05; Table 2 ), but there was an interaction in the sex, smoking, obesity, and insulin resistance subgroups.
aSSoCiatioN BetWeeN iNCReaSe iN Smi oVeR 1 yeaR WitH iNCiDeNt NaFlD
We further investigated associations between changes in SMI 1 year after baseline and risk for NAFLD among 10,534 subjects. Baseline and 1-year follow-up characteristics of the 10,534 subjects according to tertile of SMI changes over 1 year are given in Supporting Table S3 . Subjects in the highest tertile of change in SMI over a year tended to be younger, female, and have lower ASM and SMI at baseline than those in the lower tertiles. Also, compared with subjects in lower tertiles of change in SMI over a year, those in the highest tertile were more likely to have higher blood pressure and total cholesterol, and to have metabolic syndrome at baseline. Subjects with the greatest changes in SMI after 1 year had significantly reduced BMI, ALT, HOMA-IR index, total cholesterol, triglycerides, and LDL cholesterol at their 1-year follow-up visit compared with baseline values, whereas ASM and SMI markedly increased over a year. We also found that an incremental change in SMI over 1 year was negatively associated with a consistent change in HSI score over 1 year (r = −0.309, P < 0.001). As indicated in Table 3 , subjects in the highest tertile of change in SMI over a year showed a significant reduced risk of development of incident NAFLD (AHR = 0.79, 95% CI = 0.67-0.93) compared with those in lower tertiles after the adjusting for age, sex, waist circumference, diabetes, hypertension, smoking, and exercise status (model 2). Furthermore, even after adjusting for baseline SMI, the association remained significant (AHR = 0.69, 95% CI = 0.59-0.82; model 3). In addition, continuous change in SMI over 1 year showed an AHR of 0.84 (95% CI = 0.79-0.90) per percent increase in SMI over a year in association with incident NAFLD (model 3; Supporting Table S4 ). Subjects in the highest tertile of change in ASM/BMI index over 1 year also showed a significant inverse association with incident NAFLD compared with those in the lowest tertile of change in ASM/BMI, after adjustment for multiple covariates and baseline ASM/BMI index (Supporting Table S5 ).
In the subgroup analyses, the strong inverse association between SMI increases over 1 year and incident NAFLD was maintained regardless of sex, age over 50 years old, obesity, smoking status, hypertension, and insulin resistance (P for interactions > 0.05; Table 3 ). We further evaluated the frequency of maintaining a favorable change in subjects whose change in SMI at year 1 increased during the 7 years of follow-up (Supporting Table S6 ). After excluding subjects with no data on skeletal muscle mass at year 1 (n = 1174) from a total of 15,567 individuals, among 14,393 subjects, SMI increased, did not change, and decreased over 1 year in 6303 (43.8%), 15 (0.1%), and 8075 (56.1%) subjects, respectively. Of the 6303 subjects whose SMI increased over the 1 year, 4451 (70.6%) sustained a favorable change of increased SMI, and 1852 (29.4%) revealed decreased SMI at the last follow-up visit, compared with SMI at baseline. Change in SMI at year 1 from baseline was positively associated with change in SMI at the last follow-up visit from baseline (P < 0.001). In addition, subjects in the highest tertile of change in SMI at year 1 had significantly higher SMI at last follow-up visit compared with those in lower tertiles of change in SMI at year 1, after adjustment for corresponding baseline values (ANCOVA model; P < 0.001). Furthermore, we explored the relationship between change in SMI over a longer time more than 1 year and incident NAFLD. The inverse association between change in SMI over Tables S7, S8 , and S9). Change in SMI over a longer time showed a lower AHR on incident NAFLD compared with change in SMI over 1 year.
RelatioNSHip BetWeeN BaSeliNe SKeletal mUSCle maSS aND ReSolUtioN oF eXiStiNg BaSeliNe NaFlD
Among the 2943 subjects with NAFLD at baseline, NAFLD resolved only in 79 (2.7%) individuals during the 7 years of the study period. The cumulative incidence of resolution of NAFLD was significantly higher in subjects in higher tertiles of baseline SMI compared with those in the lowest tertile (Supporting Fig. S1 ; P < 0.001 by log-rank test). Compared with subjects with lowest SMI at baseline, those in the highest tertile of baseline SMI were significantly associated with the resolution of existing NAFLD (AHR = 2.09, 95% CI = 1.02-4.28) after adjusting for multiple covariates (model 2; Table 4 ). When using the ASM/BMI index, the significant association was maintained (Supporting Table S10 ).
RelatioNSHip BetWeeN iNCReaSe iN SKeletal mUSCle maSS oVeR 1 yeaR aND ReSolUtioN oF eXiStiNg BaSeliNe NaFlD
Next, we further explored the association between change in SMI over 1 year and the resolution of existing NAFLD. Supporting Table S11 provides the subject characteristics of baseline and 1-year follow-up visit according to tertile of change in SMI over 1 year among subjects having NAFLD. One year from baseline, subjects in the highest tertile of change in SMI over 1 year showed a significant reduction in body weight, BMI, AST, ALT, fasting glucose, HOMA-IR, total cholesterol, triglycerides, LDL cholesterol, and HSI score, relative to the baseline values, being the lowest among the three tertile groups at year 1. Otherwise, ASM and SMI of subjects in the highest tertile of change in SMI over 1 year were markedly increased from baseline and were the highest compared with subjects in lower tertiles at year 1. The cumulative incidence of resolution of NAFLD was significantly higher in subjects in the highest tertile of change in SMI over 1 year compared with those in the lower tertiles ( Fig. 3 ; P = 0.002 by log-rank test).
After full adjustment of all covariates including baseline SMI, the highest tertile of increase in SMI over 1 year had an increased AHR of 4.17 (95% CI = 1.90-6.17), compared with the lowest tertile of change in SMI over 1 year (model 3; Table 5 ). Furthermore, continuous change in SMI over 1 year showed an AHR of 1.99 (95% CI = 1.53-2.59) per percent increase in SMI over 1 year in association with the resolution of existing NAFLD (model 3; Table 5 , Supporting Table  S12 ). When using the ASM/BMI index, a consistent relationship was shown (Supporting Table S13 ). In subgroup analyses, the positive association between increase in SMI over 1 year and resolution of baseline existing NAFLD was consistent regardless of age over 50 years, obesity, hypertension, and insulin resistance (P for interactions > 0.05). 
Discussion
In this large 7-year longitudinal cohort study, we first examined the relationship between SMI at baseline as well as changes in SMI over time, and the development or resolution of NAFLD. We observed that SMI at baseline was inversely associated with incident NAFLD and positively associated with the resolution of existing baseline NAFLD. Moreover, an increase in SMI over 1 year has significant beneficial effects either on the development of NAFLD or the improvement of existing NAFLD, even after adjustment for glycometabolic parameters and baseline SMI.
Several studies have addressed the relationship between sarcopenia and prevalent NAFLD but were limited to cross-sectional settings. (10, 11) Skeletal muscle mass studies tend to focus on sarcopenia, or loss of muscle mass in the elderly, defined using reference cutoff values derived from sex-specific average values for healthy young adults. (34) In a sample of Caucasians, a significant association was found between sarcopenia estimated by BIA and severe steatosis defined by liver biopsy (adjusted odds ratio = 2.02, 95% CI = 1.06-3.83). (22) Lee et al. (11) reported that sarcopenia was associated with a 1.18-fold increased prevalence of NAFLD defined by HSI score independent of obesity and insulin resistance. Consistent with these results, the present 7-year longitudinal study confirmed these findings and suggested a causal link in a large sample size. Beyond sarcopenia, we revealed that greater relative skeletal muscle mass was associated with reduced risk of NAFLD in a dose-dependent manner after adjustment for multiple confounders including HOMA-IR.
The results of our study are that increased SMI over time was beneficial for either preventing developing NAFLD or resolving NAFLD in a dose-dependent manner, independent of baseline SMI. The significant relationship between change in SMI over 1 year and incident NAFLD or resolution of NAFLD was maintained in subgroup analyses of age and obesity. In addition, change in SMI over 1 year was positively associated with change in SMI over 7 years of follow-up, showing that individuals with an increase in SMI over 1 year tended to maintain the favorable change over a long time. In line with this, change in SMI over a longer time more than 1 year was also significantly associated with a reduced risk of incident NAFLD. Although the amount of increase in SMI over 1 year was relatively small, there was a significant decrease in risk by 16% for incident NAFLD per percent increase in SMI over 1 year after adjustment for glycometabolic parameters and baseline SMI, considering the annual loss in lean muscle mass as approximately 1% to 2% after age 50 years. (35, 36) In clinical contexts, these data could suggest that increase in relative skeletal muscle mass plays a favorable role in preventing or improving NAFLD in all patients, not only elderly or obese subjects. In terms of practical perspective, laypersons could simply assess change in their body composition as a percent change by subtracting baseline SMI from SMI at year 1, using BIA. Furthermore, maintaining a healthy lifestyle and habits including regular exercise, which can increase SMI, over 1 year might be helpful to sustain favorable change in SMI for a long duration of time and useful to treat NAFLD across adult patients of any age, but further studies will be needed.
The pathophysiology linking low skeletal muscle mass and NAFLD is complex and may include insulin resistance, chronic inflammation, change in myokines, and physical inactivity. (37) Skeletal muscle is the major site of insulin-mediated glucose utilization, and reduced glucose uptake caused by loss of skeletal muscle mass may contribute to insulin resistance. (38) Insulin resistance increases the uptake of free fatty acids derived from adipose tissue lipolysis to the liver, impairs suppression of gluconeogenesis, alters transport of triglycerides, and inhibits beta-oxidation, which leads to the accumulation of triglycerides in the liver. In addition, impairment of insulin signaling of the mammalian target of rapamycin pathway and inhibited growth hormone/insulin growth factor-1 axis may diminish the synthesis of muscle protein and muscle regeneration. (39) We also found that an increase in SMI was significantly inversely correlated with changes in insulin resistance and glycometabolic parameters, including HbA1C, fasting glucose, total cholesterol, triglycerides, and LDL cholesterol (data not shown). Furthermore, oxidative stress and chronic inflammation are also important for inducing synthesis of proinflammatory cytokines including tumor necrosis factor-α and transforming growth factor-β with consequent ectopic fat accumulation in the liver. (40) Skeletal muscle is considered an endocrine organ, and secretes various myokines such as irisin and IL-6. (41) (42) (43) Irisin, induced by exercise, involves peroxisome proliferator-activated receptor α signaling and plays a crucial role in fatty acid beta-oxidation in the liver, which leads to improvement of hepatic steatosis and insulin sensitivity with upregulation of fibroblast growth factor 21. (44) (45) (46) Therefore, skeletal muscle may play a causative role in developing or improving NAFLD by secreting favorable myokines. Furthermore, physical activity provides a link between relative skeletal muscle and NAFLD, as low muscle mass leads to physical disability, which reduces energy expenditures, increases obesity, and leads to hepatic steatosis. (10) Exercise itself could induce the secretion of healthy myokines from skeletal muscle and mediate skeletal muscle hypertrophy, the study of which is needed to further investigate links among relative skeletal muscle mass, exercise, and NAFLD.
This present study has several distinguishing features. It investigates the association of relative skeletal muscle mass at baseline and its change with incident NAFLD or resolution of existing baseline NAFLD across the full range of subject age. In addition, the negative relationship between baseline SMI or its increase and incident NAFLD and the positive relationship between baseline SMI or its increase and the resolution of NAFLD were all in line with the beneficial effects of relative skeletal muscle mass on NAFLD development or resolution. Moreover, we assessed SMI by BIA at multiple times during 7 years of follow-up and analyzed the change in SMI at follow-up visits and the relationship between change in SMI over a longer time and incident NAFLD. The results of this observational 7-year longitudinal study design with a large sample size, serial SMI or ASM/BMI index data, and detailed glycometabolic parameters were consistent in subgroup analyses, which strengthens the reliability of our results.
However, the present study also has potential limitations that should be considered in interpreting these results. First, we defined incident NAFLD or resolution of existing baseline NAFLD using the HSI scoring system, not by liver biopsy, which is the gold standard tool of diagnosis for NAFLD. (28) However, several recent studies have revealed external validations of HSI scores by comparing liver biopsy results and other radiologic data obtained by abdominal ultrasonography, CAP, or liver MRS in multi-ethnic samples, including large, population-based Asian samples. (30) (31) (32) Moreover, change in HSI score was reported to reflect change in fat content in the liver. (33) Therefore, the HSI score, a previously established noninvasive tool for predicting the presence or degree of NAFLD, may be practical for assessing the development of NAFLD and the resolution of existing baseline NAFLD in large population-based settings. In addition, we used HSI less than 30 as a cut-off for NAFLD resolution to conservatively avoid overestimation of the association between SMI and NAFLD resolution. Based on this cut-off, the relationship between change in SMI over a longer time and NAFLD resolution and all the subgroup analyses were not assessed due to the small number of subjects showing NAFLD resolution (n = 79, 2.7%) during the 7 years of follow-up. However, in the small number of the subjects with resolution of NAFLD in analysis, the association between change in SMI over 1 year and resolution of NAFLD remained significant. For assessing relative skeletal muscle mass, we used SMI, a body weight-adjusted ASM, because ASM is fundamentally correlated with body size. (47) SMI was proposed to be more closely associated with metabolic parameters compared with the index of ASM/height 2 . (34) Because not only ASM-but also body weight-determines SMI, and body weight change could affect SMI or NAFLD incidence or resolution, the results may not be confined to the effect of skeletal muscle mass alone. Both skeletal muscle mass and body weight need to be cautiously considered when interpreting the results regarding SMI and its change. In the present study, we adjusted for waist circumference or SMI at baseline in multivariate-adjusted analyses and additionally adopted another ASM/BMI index, showing consistent results when using SMI. Furthermore, although we fully adjusted for various potential confounders, specific exercise status regarding type, frequency, or duration, or information about whether subjects were taking nutritional supplements that could affect skeletal muscle mass, were not available in the present study. Finally, this study was based on a sample of Korean individuals who participated in health check-up examinations, which may limit the ability to generalize our results to other settings or other ethnicities.
In conclusion, relative skeletal muscle mass is positively associated with the development of NAFLD and negatively associated with the resolution of existing NAFLD. Moreover, increase in relative skeletal muscle mass over time may play an important role in developing NAFLD and improving the resolution of existing baseline NAFLD after adjustment for baseline relative skeletal muscle mass values across individuals of all ages. Considering the increasing rate of NAFLD worldwide and lack of approved drug therapy for NAFLD, our findings may shed light on potential preventive and therapeutic interventions to treat NAFLD.
